Jazz Pharmaceuticals Denmark ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.1% 2.2% 2.2% 2.0% 2.4%  
Credit score (0-100)  21 65 65 68 62  
Credit rating  BB BBB BBB A BBB  
Credit limit (kDKK)  0.0 0.3 0.7 2.3 0.2  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  7,280 16,469 30,364 30,364 31,788  
EBITDA  -364 2,168 3,388 3,388 2,242  
EBIT  -364 2,168 3,388 3,388 2,242  
Pre-tax profit (PTP)  -622.0 1,834.6 1,978.8 1,978.8 1,615.9  
Net earnings  -483.7 1,540.5 1,972.9 1,972.9 595.2  
Pre-tax profit without non-rec. items  -622 1,835 1,979 1,979 1,616  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  6,088 7,629 10,162 10,162 10,757  
Interest-bearing liabilities  0.0 7,637 9,225 9,225 12,324  
Balance sheet total (assets)  9,503 22,785 27,479 27,479 36,081  

Net Debt  -2,502 5,784 7,778 7,778 6,667  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  7,280 16,469 30,364 30,364 31,788  
Gross profit growth  0.0% 126.2% 84.4% 0.0% 4.7%  
Employees  3 8 16 16 17  
Employee growth %  0.0% 166.7% 100.0% 0.0% 6.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  9,503 22,785 27,479 27,479 36,081  
Balance sheet change%  0.0% 139.8% 20.6% 0.0% 31.3%  
Added value  -363.9 2,167.9 3,387.6 3,387.6 2,241.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 1.0 2.0 3.0 4.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -5.0% 13.2% 11.2% 11.2% 7.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -3.8% 13.4% 13.5% 12.3% 7.1%  
ROI %  -6.0% 20.3% 19.6% 17.5% 10.7%  
ROE %  -7.9% 22.5% 22.2% 19.4% 5.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  64.1% 33.5% 37.0% 37.0% 29.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  687.5% 266.8% 229.6% 229.6% 297.4%  
Gearing %  0.0% 100.1% 90.8% 90.8% 114.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 8.7% 16.7% 15.3% 6.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.8 1.0 1.1 1.1 1.2  
Current Ratio  2.8 1.5 1.6 1.6 1.4  
Cash and cash equivalent  2,501.9 1,852.8 1,447.4 1,447.4 5,657.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  6,088.0 7,628.5 10,161.7 10,161.7 10,756.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -121 271 212 212 132  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -121 271 212 212 132  
EBIT / employee  -121 271 212 212 132  
Net earnings / employee  -161 193 123 123 35